Gil'deeva G N, Kudlai D A, Luk'yanov S V
Eksp Klin Farmakol. 2015;78(12):51-6.
Rituximab is a chimeric monoclonal antibody containing constant kappa-regions of the Fc fragment of IgGI human immunoglobulin and variable fragments of IgG murine immunoglobulin. This modified immunoglobulin structure makes rituximab capable of specifically recognizing CD20 antigen that is mainly expressed on B-lymphocytes. The review considers four main mechanisms of rituximab action leading to reduction of the population of B-lymphocytes in patients with lymphoproliferative processes. All these mechanisms are probably operative under clinical conditions, however, their relative contributions to the clinical effect of rituximab can vary and are yet not defined in full.
利妥昔单抗是一种嵌合单克隆抗体，包含人免疫球蛋白IgG1的Fc片段的恒定κ区域和鼠免疫球蛋白IgG的可变片段。这种修饰的免疫球蛋白结构使利妥昔单抗能够特异性识别主要在B淋巴细胞上表达的CD20抗原。该综述探讨了利妥昔单抗作用的四种主要机制，这些机制导致淋巴细胞增殖性疾病患者的B淋巴细胞数量减少。所有这些机制在临床条件下可能都起作用，然而，它们对利妥昔单抗临床效果的相对贡献可能不同，且尚未完全明确。
